Abstract
Cancer is most curable when it is smallest, yet the majority of solid tumours are still discovered only after they declare themselves through mass effect, systemic illness, or incidental imaging. The eye offers a quietly remarkable alternative: it is the only site in the body where neural tissue, its blood supply, and the microvasculature can be inspected non-invasively, in vivo, and at subcellular resolution through an ordinary dilated fundus examination. This narrative review explores how visual symptoms and ocular signs—paraneoplastic retinopathies, distant metastases to the uveal tract, neuro ophthalmic syndromes, and so-called masquerade phenomena—may precede the clinical detection of an underlying malignancy, sometimes by months or even years.
References
1. Beuzit S, et al. Paraneoplastic ocular syndromes: a systematic review of epidemiology, diagnosis and outcomes (2010–2023). Int Ophthalmol. 2025;45:s12348 025-00534-1.
2. Rahimy E, Sarraf D. Paraneoplastic and related retinopathies: an update on pathogenesis, diagnosis and management. Ann Eye Sci. 2024;9:7643.
3. Rishi P, Rishi A, Gupta H, Swaminathan M, Chhablani J. Insights into retinal metastasis from systemic carcinoma. J Clin Med. 2024;13(20):6037.
4. Garrido-Hermosilla AM, et al. GATA-3 biomarker as a confounding factor in a patient with intraocular metastasis from squamous cell carcinoma of the lung. Arch Soc
Esp Oftalmol. 2025.
5. Li D, et al. Retinal metastasis from lung adenocarcinoma: a case report. Front Oncol.
2025;15:1616331

This work is licensed under a Creative Commons Attribution 4.0 International License.